Cargando…
Decreased resistin plasmatic concentrations in patients with Alzheimer's disease: A case-control study
Previous studies suggested a role for adipokines in ageing and in several age-related diseases. The purpose of our study was to further elucidate adipokines involvement in neurodegeneration, investigating adiponectin, leptin and resistin in Alzheimer's disease (AD) and Frontotemporal Dementia (...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9694389/ https://www.ncbi.nlm.nih.gov/pubmed/36439765 http://dx.doi.org/10.1016/j.heliyon.2022.e11738 |
_version_ | 1784837787732672512 |
---|---|
author | Marcinnò, Andrea Gallo, Erica Roveta, Fausto Boschi, Silvia Grassini, Alberto Rainero, Innocenzo Rubino, Elisa |
author_facet | Marcinnò, Andrea Gallo, Erica Roveta, Fausto Boschi, Silvia Grassini, Alberto Rainero, Innocenzo Rubino, Elisa |
author_sort | Marcinnò, Andrea |
collection | PubMed |
description | Previous studies suggested a role for adipokines in ageing and in several age-related diseases. The purpose of our study was to further elucidate adipokines involvement in neurodegeneration, investigating adiponectin, leptin and resistin in Alzheimer's disease (AD) and Frontotemporal Dementia (FTD). We enrolled for the study 70 subjects: 26 AD, 21 FTD, and 23 with other neurological (but not neurodegenerative) conditions (CTR, control group). According to a standardized protocol, we measured adipokines plasmatic levels, blood parameters of glucidic and lipidic metabolism, ESR, cerebrospinal fluid (CSF) markers of neurodegeneration (beta-amyloid, total-Tau, phosphorylated-Tau) and anthropometric parameters. In comparison with control group, we found lower resistin concentrations in patients with dementia, and in particular in AD (p < 0.001). In multivariate analysis, AD relative risk was reduced by resistin, when controlling for sex, age and anthropometric/metabolic parameters (RR = 0.71, P < 0.0001). Considering CSF biomarkers, we found a direct correlation between resistin and Aβ(1-42) CSF concentration in patients (p < 0.001, r = 0.50). Lower resistin characterized AD patients in our study and AD, but not FTD, diagnosis risk was found to be inversely associated with resistin when controlling for confounders. We hypothesize that resistin-linked metabolic profile has to be reconsidered and further investigated in AD. |
format | Online Article Text |
id | pubmed-9694389 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-96943892022-11-26 Decreased resistin plasmatic concentrations in patients with Alzheimer's disease: A case-control study Marcinnò, Andrea Gallo, Erica Roveta, Fausto Boschi, Silvia Grassini, Alberto Rainero, Innocenzo Rubino, Elisa Heliyon Research Article Previous studies suggested a role for adipokines in ageing and in several age-related diseases. The purpose of our study was to further elucidate adipokines involvement in neurodegeneration, investigating adiponectin, leptin and resistin in Alzheimer's disease (AD) and Frontotemporal Dementia (FTD). We enrolled for the study 70 subjects: 26 AD, 21 FTD, and 23 with other neurological (but not neurodegenerative) conditions (CTR, control group). According to a standardized protocol, we measured adipokines plasmatic levels, blood parameters of glucidic and lipidic metabolism, ESR, cerebrospinal fluid (CSF) markers of neurodegeneration (beta-amyloid, total-Tau, phosphorylated-Tau) and anthropometric parameters. In comparison with control group, we found lower resistin concentrations in patients with dementia, and in particular in AD (p < 0.001). In multivariate analysis, AD relative risk was reduced by resistin, when controlling for sex, age and anthropometric/metabolic parameters (RR = 0.71, P < 0.0001). Considering CSF biomarkers, we found a direct correlation between resistin and Aβ(1-42) CSF concentration in patients (p < 0.001, r = 0.50). Lower resistin characterized AD patients in our study and AD, but not FTD, diagnosis risk was found to be inversely associated with resistin when controlling for confounders. We hypothesize that resistin-linked metabolic profile has to be reconsidered and further investigated in AD. Elsevier 2022-11-21 /pmc/articles/PMC9694389/ /pubmed/36439765 http://dx.doi.org/10.1016/j.heliyon.2022.e11738 Text en © 2022 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Research Article Marcinnò, Andrea Gallo, Erica Roveta, Fausto Boschi, Silvia Grassini, Alberto Rainero, Innocenzo Rubino, Elisa Decreased resistin plasmatic concentrations in patients with Alzheimer's disease: A case-control study |
title | Decreased resistin plasmatic concentrations in patients with Alzheimer's disease: A case-control study |
title_full | Decreased resistin plasmatic concentrations in patients with Alzheimer's disease: A case-control study |
title_fullStr | Decreased resistin plasmatic concentrations in patients with Alzheimer's disease: A case-control study |
title_full_unstemmed | Decreased resistin plasmatic concentrations in patients with Alzheimer's disease: A case-control study |
title_short | Decreased resistin plasmatic concentrations in patients with Alzheimer's disease: A case-control study |
title_sort | decreased resistin plasmatic concentrations in patients with alzheimer's disease: a case-control study |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9694389/ https://www.ncbi.nlm.nih.gov/pubmed/36439765 http://dx.doi.org/10.1016/j.heliyon.2022.e11738 |
work_keys_str_mv | AT marcinnoandrea decreasedresistinplasmaticconcentrationsinpatientswithalzheimersdiseaseacasecontrolstudy AT galloerica decreasedresistinplasmaticconcentrationsinpatientswithalzheimersdiseaseacasecontrolstudy AT rovetafausto decreasedresistinplasmaticconcentrationsinpatientswithalzheimersdiseaseacasecontrolstudy AT boschisilvia decreasedresistinplasmaticconcentrationsinpatientswithalzheimersdiseaseacasecontrolstudy AT grassinialberto decreasedresistinplasmaticconcentrationsinpatientswithalzheimersdiseaseacasecontrolstudy AT raineroinnocenzo decreasedresistinplasmaticconcentrationsinpatientswithalzheimersdiseaseacasecontrolstudy AT rubinoelisa decreasedresistinplasmaticconcentrationsinpatientswithalzheimersdiseaseacasecontrolstudy |